Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Anthony Velasco, On Behalf of Himself and All Others Similarly Situated v. Sei Pharmaceuticals

January 25, 2013

ANTHONY VELASCO, ON BEHALF OF HIMSELF AND ALL OTHERS SIMILARLY SITUATED,
PLAINTIFFS,
v.
SEI PHARMACEUTICALS, INC., A FLORIDA CORPORATION, AND DOES 1-10, INCLUSIVE, DEFENDANTS.



The opinion of the court was delivered by: Hayes, Judge:

ORDER

The matter before the Court is the Motion for Leave to File First Amended Complaint filed by Plaintiff Anthony Velasco. (ECF No. 14).

I. Background

On April 30, 2012, Plaintiff initiated this action by filing a Complaint in this Court. (ECF No. 1).

On June 1, 2012, Defendant SEI Pharmaceuticals, Inc. filed a Motion to Dismiss the Complaint. (ECF No. 5). On October 29, 2012, the Court granted the Motion to Dismiss and dismissed the Complaint without prejudice. (ECF No. 12).

On November 26, 2012, Plaintiff filed the Motion for Leave to File First Amended Complaint, accompanied by a proposed first amended complaint. (ECF No. 14).

On December 10, 2012, Defendant filed an opposition to the Motion for Leave to File First Amended Complaint. (ECF No. 16). Defendant contends:

Plaintiff's Motion for Leave to File a First Amended Complaint should be denied. Plaintiff's proposed FAC fails to cure the defects contained within his original Complaint which was dismissed by the Court. Plaintiff's proposed FAC fails to allege cognizable claims under the [California Unfair Competition Law], [California Consumer Legal Remedies Act] and False Advertising laws. Further, Plaintiff's claims fall within the primary jurisdiction of the FDA and under that doctrine, the Court should defer to the regulatory authority of the FDA.

Id. at 16.

On December 17, 2012, Plaintiff filed a reply brief. (ECF No. 17). Plaintiff contends that "Defendant has brought up only repeat arguments from its Motion to Dismiss and does not even address the [Federal Rules of Civil Procedure] 8(a) or 9(b) arguments that were the reason for the Court granting dismissal of the Complaint." Id. at 3. Plaintiff contends: "[B]y failing to address the adequacy of those amendments in opposition to Plaintiff's Motion for Leave to Amend, Defendant should further be precluded from raising questions about the adequacy of those amendments in a subsequent Motion to Dismiss." Id.

II. Discussion

Rule 15 of the Federal Rules of Civil Procedure mandates that leave to amend "be freely given when justice so requires." Fed. R. Civ. P. 15(a). "This policy is to be applied with extreme liberality." Eminence Capital, LLC v. Aspeon, Inc., 316 F.3d 1048, 1051 (9th Cir. 2003) (quotation omitted). In Foman v. Davis, 371 U.S. 178 (1962), the Supreme Court offered several factors for district courts to consider in deciding whether to grant a motion to amend under Rule 15(a):

In the absence of any apparent or declared reason--such as undue delay, bad faith or dilatory motive on the part of the movant, repeated failure to cure deficiencies by amendments previously allowed, undue prejudice to the opposing party by virtue of allowance of the amendment, futility of amendment, etc.--the leave sought should, as the rules require, be 'freely given.'

Foman, 371 U.S. at 182; see also Smith v. Pac. Prop. Dev. Co., 358 F.3d 1097, 1101 (9th Cir. ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.